Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) and Emergent Biosolutions (NYSE:EBS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.
Risk and Volatility
Sarepta Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Emergent Biosolutions has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500.
Profitability
This table compares Sarepta Therapeutics and Emergent Biosolutions’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sarepta Therapeutics | -5.86% | -0.20% | -0.09% |
| Emergent Biosolutions | -40.16% | -0.43% | -0.15% |
Institutional & Insider Ownership
86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Sarepta Therapeutics and Emergent Biosolutions”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sarepta Therapeutics | $1.96 billion | 0.86 | -$713.41 million | ($1.37) | -11.41 |
| Emergent Biosolutions | $626.70 million | 0.48 | $52.60 million | ($5.10) | -1.15 |
Emergent Biosolutions has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Sarepta Therapeutics and Emergent Biosolutions, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sarepta Therapeutics | 6 | 6 | 6 | 0 | 2.00 |
| Emergent Biosolutions | 2 | 1 | 3 | 0 | 2.17 |
Sarepta Therapeutics currently has a consensus price target of $23.67, suggesting a potential upside of 51.47%. Emergent Biosolutions has a consensus price target of $10.00, suggesting a potential upside of 71.00%. Given Emergent Biosolutions’ stronger consensus rating and higher possible upside, analysts plainly believe Emergent Biosolutions is more favorable than Sarepta Therapeutics.
Summary
Sarepta Therapeutics beats Emergent Biosolutions on 9 of the 14 factors compared between the two stocks.
About Sarepta Therapeutics
Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.
About Emergent Biosolutions
Emergent BioSolutions is a biopharmaceutical company focused on products that address public health threats and medical emergencies. Its portfolio includes vaccines and treatments for infectious diseases, opioid overdose and other health risks, with customers that include governments and healthcare providers. Products associated with the company include BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; and NARCAN, a naloxone nasal spray used to reverse opioid overdose. Emergent also provides contract development and manufacturing services for pharmaceutical and biotechnology organizations.
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
